60 Degrees Pharmaceuticals (SXTP) Partners With USM to Study Castanospermine for AGS

What happened

60 Degrees Pharmaceuticals signed a sponsored research agreement with The University of Southern Mississippi to test castanospermine in nonclinical models of alpha-gal syndrome. The company will explore botanical approval pathways before starting a prescription drug program.

Confirmed

Global impact / market context

This moves the small drugmaker beyond malaria into an allergy with no approved treatment, which means wider potential revenue. The USM option to license intellectual property could give exclusive rights if early lab data look good, reducing the risk of later partnership deals.

Analyst inference

Alpha-gal syndrome is a tick-linked allergy, and the article describes it as an unmet need with no FDA-approved therapies. For investors, this is an early lab-stage step, so the possible payoff depends on future study results and a clear regulatory route with cost and funding details.

Analyst inference

What to watch

1. The company plans to assess castanospermine in nonclinical models, so the first readouts will show whether the compound works well enough to justify moving toward human testing. Confirmed
2. The agreement includes an option to commercialize USM intellectual property, which means investors should watch whether positive data lead the company to exercise that right. Proposed
3. The botanical approval route could cut cost and time compared with a full prescription path, so any stated timeline and funding plan will signal how quickly this program can advance. Analyst inference

Evidence

• globenewswire.com